# Curie.Bio

Curie.Bio is a Private Equity based in Cambridge, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, United States
- **Founded:** 2022
- **Assets under management:** Undisclosed
- **Website:** curie.bio
- **LinkedIn:** https://www.linkedin.com/company/curie-bio

## Regulatory record

- **CRD number:** 323682
- **SEC file number:** 802-126921
- **Reports private funds:** No
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/323682

## About

Curie.Bio was established as a private equity vehicle. No founding year or named principals are disclosed in available sources. The firm pursues early-stage seed investments. No portfolio companies, co-investors, or geographic allocations beyond headquarters are recorded. No fund structures or direct co-investment activity is documented. Team size, additional offices, and adjacent vehicles remain undisclosed. No operational events from the last 24 months are verifiable. No structural differentiators such as succession plans or hybrid mandates are observable from current data.

## Sectors

- Biotech
- Healthcare Services

## Questions

### What makes Curie.Bio structurally different from a standard biotech venture capital firm?

Curie.Bio embeds a full-stack drug-development team inside seed-stage therapeutics companies, acting as a hands-on operating partner rather than a board-level investor. The firm provides capital alongside in-house expertise in CMC, clinical trial design, and regulatory strategy. This model shifts the primary value proposition from financial allocation to operational de-risking of preclinical and early clinical assets.

### At what stage does Curie.Bio invest?

Curie.Bio targets the seed stage for therapeutics companies, with the explicit goal of preparing each portfolio company for a Series A or equivalent next round of financing. The firm's engagement is built around a concentrated window of 18 to 24 months of operational lift to make the science fundable by larger institutional investors.

### Who makes investment decisions at Curie.Bio?

The firm has not publicly disclosed its partnership structure or investment committee. Altss research identifies no named principals, managing partners, or listed leadership team. Curie.Bio's website and available public materials reference a team of drug hunters and company builders but provide no individual biographies.

### Does Curie.Bio operate more like a venture firm or a drug-discovery incubator?

Curie.Bio operates as a hybrid: it provides seed capital like a venture firm but embeds operational teams like an incubator. Unlike most incubators, however, it does not originate the science internally — it backs external academic or entrepreneurial founders and layers on its cross-functional team to advance the program toward a financing milestone.

### What is Curie.Bio's known track record for follow-on financing?

The firm has not publicly disclosed its portfolio companies, names of therapeutics programs, or a record of post-seed financing rounds closed by its companies. As of the latest Altss review cycle, no verifiable funding outcomes are attributable to Curie.Bio in the public domain.

## Related profiles

- [Curewell Capital](https://altss.com/profile/curewell-capital)
- [Curie Capital](https://altss.com/profile/curie-capital)

---

Last updated: 2026-07-06T00:32:37.905Z

Canonical page: https://altss.com/profile/curie-bio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology